Table 3 Univariate analysis of prognostic factors for progression-free and overall survival.
Characteristic | PFS, months | HR (95% CI)a | p-valuea | OS, months | HR (95% CI)a | p-valuea |
|---|---|---|---|---|---|---|
Gender | ||||||
Male | 4.2 | 1.233 (0.6–2.7) | 0.599 | 8.1 | 1.186 (0.5–2.9) | 0.704 |
Female | 4.7 | – | – | 11.1 | – | – |
ECOG PS | ||||||
0–1 | 4.7 | 0.652 (0.3–1.6) | 0.336 | 9.3 | 0.517 (0.2–1.4) | 0.182 |
2 | 3.5 | – | – | 8.1 | – | – |
Histological grade | ||||||
G1–G2 | 4.7 | 0.424 (0.1–1.9) | 0.247 | 10.6 | 0.087 (0.1–0.5) | 0.001 |
G3 | 2.5 | – | – | 3.4 | – | – |
Tumour presentation | ||||||
Synchronous | 4.0 | 2.391 (0.9–5.7) | 0.053 | 9.3 | 1.017 (0.4–2.6) | 0.971 |
Metachronous | 6.0 | – | – | 10.6 | – | – |
Tumour surgery | ||||||
No | 2.8 | 1.044 (0.4–3.0) | 0.937 | 5.3 | 1.396 (0.5–4.3) | 0.562 |
Yes | 4.3 | – | – | 9.3 | – | – |
Metastatic sites | ||||||
< 3 | 3.0 | 2.286 (1.0–5.1) | 0.001 | 5.2 | 2.790 (0.9–7.8) | 0.06 |
≥3 | 8.2 | – | – | 17.7 | – | – |
Liver metastases | ||||||
No | 17.5 | 0.309 (0.1–1.1) | 0.069 | 8.1 | 0.782 (0.2–2.7) | 0.696 |
Yes | 4.0 | – | – | 9.3 | – | – |
Peritoneal metastases | ||||||
No | 4.7 | 0.393 (0.1–0.9) | 0.046 | 9.3 | 0.437 (0.2–1.0) | 0.07 |
Yes | 2.8 | – | – | 5.6 | – | – |
Time from metastatic disease diagnosis | ||||||
≥18 months | 4.3 | 0.763 (0.3–1.8) | 0.523 | 9.3 | 0.871 (0.3–2.3) | 0.780 |
< 18 months | 4.8 | – | – | 17.7 | – | – |
Tabernero prognostic classification | ||||||
Best | NR | – | 0.069 | NR | – | 0.071 |
Good | 5.0 | – | – | 11.1 | – | – |
Poor | 3.5 | – | – | 7.9 | – | – |
